Drug Profile
LY 3108743
Alternative Names: LY-3108743Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Singapore (PO, Capsule)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Singapore (PO, Liquid)
- 30 Apr 2014 Eli Lilly completes a phase I trial in Type-2 diabetes mellitus in Singapore (NCT01995656)